Neratinib/Capecitabine vs Lapatinib/Capecitabine for Pretreated Patients With HER2-Positive Metastatic Breast Cancer – The ASCO Post

By Matthew Stenger Posted: 8/3/2020 10:00:00 AM Last Updated: 8/4/2020 9:49:50 AM As reported in the Journal of Clinical Oncology by Cristina Saura, MD, and colleagues, the phase III NALA trial has shown significantly prolonged progression-free survival with…

Read the full article here

Related Articles